<bill session="116" type="s" number="660" updated="2022-11-01T17:03:24Z">
  <state datetime="2019-03-05">REFERRED</state>
  <status>
    <introduced datetime="2019-03-05"/>
  </status>
  <introduced datetime="2019-03-05"/>
  <titles>
    <title type="display">Efficiency and Transparency in Petitions Act</title>
    <title type="short" as="introduced">Efficiency and Transparency in Petitions Act</title>
    <title type="official" as="introduced">A bill to address abuse of the Food and Drug Administration's citizen petition process by brand drug manufacturers.</title>
  </titles>
  <sponsor bioguide_id="B001310"/>
  <cosponsors/>
  <actions>
    <action datetime="2019-03-05">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2019-03-05" state="REFERRED">
      <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
    </action>
  </actions>
  <committees>
    <committee code="SSHR" name="Senate Health, Education, Labor, and Pensions" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Administrative remedies"/>
    <term name="Department of Health and Human Services"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Government information and archives"/>
  </subjects>
  <amendments/>
  <summary date="2021-09-13T15:23:16Z" status="Introduced in Senate">Efficiency and Transparency in Petitions Act

This bill requires a petition regarding a pending generic drug or biological product application to be submitted to the Food and Drug Administration (FDA)within one year of when the petitioner discovers the issue that is the basis for the petition.

The FDA may grant a waiver of the one-year deadline.</summary>
</bill>
